July 21, 2023 07:11 AM EDT
People
R&D

Codex­is cuts 25% of staff, slash­es drug pro­grams while dou­bling down on RNAi tech

Amber Tong

The en­zyme en­gi­neer­ing spe­cial­ists at Codex­is are giv­ing up on mak­ing their own ther­a­pies, in­stead fo­cus­ing on sell­ing its tech­nolo­gies and ser­vices to cus­tomers …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

A service from the Financial Times